BIOTINE OINTMENT 3% W/W

Product Information

Registration Status: Active

BIOTINE OINTMENT 3% W/W is approved to be sold in Singapore with effective from 1996-05-01. It is marketed by ICM PHARMA PTE LTD, with the registration number of SIN08514P.

This product contains Tetracycline 3% w/w in the form of OINTMENT. It is approved for TOPICAL use.

This product is manufactured by ICM PHARMA PTE LTD in SINGAPORE.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Tetracycline

Description

A tetracycline with a 7-chloro substitution.

Indication

For the treatment of infections and to treat acne. It may also be used to treat urinary tract infections, gum disease, and other bacterial infections such as gonorrhea and chlamydia. Lymecycline is also used commonly as a prophylactic treatment for infection by Bacillus anthracis (anthrax). It is also effective against Yersinia pestis and malaria and is also prescribed for the treatment of Lyme disease.

Mechanism of Action

Lymecycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Lymecycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. Cells become resistant to lymecycline by at least two mechanisms: efflux and ribosomal protection. In efflux, a resistance gene encodes a membrane protein that actively pumps lymecycline out of the cell. This is the mechanism of action of the tetracycline resistance gene on the artificial plasmid pBR322. In ribosomal protection, a resistance gene encodes a protein which binds to the ribosome and prevents lymecycline from acting on the ribosome.

Pharmacokinetics

Absorption
Absorption is fast and efficient. Bioavailability is 100% following oral administration.
Distribution
Metabolism
Elimination

Toxicity

Adverse effects include nausea, vomiting, diarrhoea, glossitis, enterocolitis, dysphagia, dermatitis, hypersensitivity reactions, proctitis, and vaginitis.

Active Ingredient/Synonyms

(+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide | Limeciclina | Lymecyclinum | N-Lysinomethyltetracycline | N2-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline | N6-((4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido)methyl)lysine | Tetracycline-L-methylene lysine | Tetracycline-L-methylenelysine | Lymecycline |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank